Status:
RECRUITING
Therapeutic Orientation Test in Thrombotic Microangiopathy
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Thrombotic Micro-angiopathy
Eligibility:
All Genders
Up to 90 years
Phase:
NA
Brief Summary
Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich block al...
Eligibility Criteria
Inclusion
- TMA with:
- mechanic haemolytic anemia, undetectable haptoglobin, LDH\>1.5\*LNS
- thrombopenia
- acute kidney injury TMA on native kidney or in post-transplantation.
Exclusion
- DIVC patients
- plasma exchange during 1 month before sample collection
- treatment by Eculizumab before sample collection
- no consent
- not beneficiary of a social security
- pregnancy or breastfeeding
- patient Under guardianship
Key Trial Info
Start Date :
April 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 3 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04777435
Start Date
April 3 2021
End Date
April 3 2027
Last Update
July 23 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France
2
Site Médipôle Cabestany
Cabestany, France
3
Centre Nephrocare Castelnau-le-Lez
Castelnau-le-Lez, France
4
CHU de Grenoble
Grenoble, France